Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Comment

Following positive Phase IIb data, Shield Therapeutics aims to initiate Phase III study for phosphate binder PT20 by 2022

Close
Close
Close

Go Top